The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

A 32-Year-Old Female with Incidentally Detected Multifocal Cystic Pulmonary Lesions on Chest Computed Tomography

흉부 CT에서 우연히 발견된 다발성 낭성 폐병변을 가진 32세 여성

  • Hee-Young Yoon (Division of Allergy and Respiratory Diseases, Department of Internal Medicine, Soonchunhyang University Hospital Seoul, Soonchunhyang University College of Medicine)
  • 윤희영 (순천향대학교 의과대학 순천향대학교 서울병원 호흡기알레르기내과)
  • Received : 2023.11.21
  • Accepted : 2024.01.23
  • Published : 2024.02.01
Download PDF
⟨ Previous Next ⟩

Abstract

Lymphangioleiomyomatosis (LAM) is a rare condition that exclusively affects women and is characterized by lung parenchymal destruction and the formation of cysts due to infiltration by LAM cells. It can also impact the lymphatic system, leading to the development of fluid-filled cystic structures and abdominal involvement, including renal angiomyolipomas (AML) or lymphangioleiomyoma. LAM can occur sporadically or be associated with tuberous sclerosis complex. Common symptoms include respiratory issues such as dyspnea, pneumothorax, chylothorax, along with other manifestations like renal AML and lymphatic involvement. The diagnosis of LAM relies on a combination of clinical, radiological, and laboratory findings, and treatment options vary depending on symptoms and patient status, with mTOR inhibitors being considered as a treatment option. This case outlines the diagnostic journey and clinical course of a 32-year-old female patient with LAM.

Keywords

Acknowledgement

This paper was supported by Soonchunhyang University Research Fund.

References

  1. Gupta N, Vassallo R, Wikenheiser-Brokamp KA, McCormack FX. Diffuse cystic lung disease. Part I. Am J Respir Crit Care Med 2015;191:1354-1366. https://doi.org/10.1164/rccm.201411-2094CI
  2. McCormack FX, Travis WD, Colby TV, Henske EP, Moss J. Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm. Am J Respir Crit Care Med 2012;186:1210-1212. https://doi.org/10.1164/rccm.201205-0848OE
  3. Moss J, Avila NA, Barnes PM, et al. Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex. Am J Respir Crit Care Med 2001;164:669-671. https://doi.org/10.1164/ajrccm.164.4.2101154
  4. Cudzilo CJ, Szczesniak RD, Brody AS, et al. Lymphangioleiomyomatosis screening in women with tuberous sclerosis. Chest 2013;144:578-585. https://doi.org/10.1378/chest.12-2813
  5. Harknett EC, Chang WY, Byrnes S, et al. Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis. QJM 2011;104:971-979. https://doi.org/10.1093/qjmed/hcr116
  6. Ryu JH, Moss J, Beck GJ, et al. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med 2006;173:105-111. https://doi.org/10.1164/rccm.200409-1298OC
  7. Young L, Lee HS, Inoue Y, et al. Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the multicenter international lymphangioleiomyomatosis efficacy of sirolimus (MILES) trial. Lancet Respir Med 2013;1:445-452. https://doi.org/10.1016/S2213-2600(13)70090-0
  8. Gupta N, Lee HS, Ryu JH, et al. The NHLBI LAM registry: prognostic physiologic and radiologic biomarkers emerge from a 15-year prospective longitudinal analysis. Chest 2019;155:288-296. https://doi.org/10.1016/j.chest.2018.06.016
  9. Seo JY, Kim A, Baek YS, Jeon J. Successful long-term multimodality management of facial lesions in tuberous sclerosis complex in an adult patient. Ann Dermatol 2023;35 Suppl 2:S243-S246. https://doi.org/10.5021/ad.21.235
  10. Hasal E, Baskan EB, Gul S, et al. Birt-Hogg-Dube syndrome: diagnostic journey of three cases from skin to gene. Ann Dermatol 2022;34:66-71. https://doi.org/10.5021/ad.2022.34.1.66
  11. Shin WW, Baek YS, Oh TS, et al. Birt-Hogg-Dube syndrome, a rare case in Korea confirmed by genetic analysis. Ann Dermatol 2011;23 Suppl 2:S193-S196. https://doi.org/10.5021/ad.2011.23.S2.S193
  12. O'Mahony AM, Lynn E, Murphy DJ, Fabre A, McCarthy C. Lymphangioleiomyomatosis: a clinical review. Breathe (Sheff) 2020;16:200007.
  13. Gupta N, Finlay GA, Kotloff RM, et al. Lymphangioleiomyomatosis diagnosis and management: high-resolution chest computed tomography, transbronchial lung biopsy, and pleural disease management. An Official American Thoracic Society/Japanese Respiratory Society clinical practice guideline. Am J Respir Crit Care Med 2017;196:1337-1348. https://doi.org/10.1164/rccm.201709-1965ST
  14. McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011;364:1595-1606. https://doi.org/10.1056/NEJMoa1100391
  15. Gupta N, Lee HS, Young LR, et al. Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis. Eur Respir J 2019;53:1802066.